↓ Skip to main content

Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response

Overview of attention for article published in Breast Cancer Research, October 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (92nd percentile)
  • High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news
1 news outlet
twitter
18 tweeters
facebook
2 Facebook pages
googleplus
1 Google+ user

Citations

dimensions_citation
42 Dimensions

Readers on

mendeley
97 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response
Published in
Breast Cancer Research, October 2015
DOI 10.1186/s13058-015-0642-8
Pubmed ID
Authors

Esther H. Lips, Magali Michaut, Marlous Hoogstraat, Lennart Mulder, Nicolle JM Besselink, Marco J. Koudijs, Edwin Cuppen, Emile E. Voest, Rene Bernards, Petra M. Nederlof, Jelle Wesseling, Sjoerd Rodenhuis, Lodewyk FA Wessels

Abstract

In triple negative breast cancers (TNBC) the initial response to chemotherapy is often favorable, but relapse and chemotherapy resistance frequently occur in advanced disease. Hence there is an urgent need for targeted treatments in this breast cancer subtype. In the current study we deep sequenced DNA of tumors prior to chemotherapy to search for predictors of response or resistance. Next generation sequencing (NGS) was performed for 1,977 genes involved in tumorigenesis. DNA from 56 pre-treatment TNBC-biopsies was sequenced, as well as matched normal DNA. Following their tumor biopsy, patients started neoadjuvant chemotherapy with doxorubicin and cyclophosphamide. We studied associations between genetic alterations and three clinical variables: chemotherapy response, relapse-free survival and BRCA proficiency. The mutations observed were diverse and few recurrent mutations were detected. Most mutations were in TP53, TTN, and PIK3CA (55 %, 14 %, and 9 %, respectively). The mutation rates were similar between responders and non-responders (average mutation rate 9 vs 8 mutations). No recurrent mutations were associated with chemotherapy response or relapse. Interestingly, PIK3CA mutations were exclusively observed in patients proficient for BRCA1. Samples with a relapse had a higher copy number alteration rate, and amplifications of TTK and TP53BP2 were associated with a poor chemotherapy response. In this homogenous cohort of TNBCs few recurrent mutations were found. However, PIK3CA mutations were associated with BRCA proficiency, which can have clinical consequences in the near future.

Twitter Demographics

The data shown below were collected from the profiles of 18 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 97 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 1%
Spain 1 1%
Unknown 95 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 20 21%
Student > Master 18 19%
Student > Ph. D. Student 14 14%
Other 8 8%
Student > Doctoral Student 7 7%
Other 20 21%
Unknown 10 10%
Readers by discipline Count As %
Medicine and Dentistry 28 29%
Biochemistry, Genetics and Molecular Biology 28 29%
Agricultural and Biological Sciences 18 19%
Computer Science 4 4%
Pharmacology, Toxicology and Pharmaceutical Science 2 2%
Other 3 3%
Unknown 14 14%

Attention Score in Context

This research output has an Altmetric Attention Score of 21. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 February 2016.
All research outputs
#752,105
of 13,453,331 outputs
Outputs from Breast Cancer Research
#83
of 1,510 outputs
Outputs of similar age
#19,906
of 252,826 outputs
Outputs of similar age from Breast Cancer Research
#1
of 18 outputs
Altmetric has tracked 13,453,331 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,510 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.0. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 252,826 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.